Eyad Alsabbagh, MD
Interventional Pain Medicine · Brooksville, FLNPI 1295789444
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,240 of the $4,723 with a category attached, or 68.6%. Gilead accounts for 95.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $4,508 and has fallen 99.5% since, to $21 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in FL, where the typical reported total is $4,625.
Across 9 payments — averaging $524.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Stimwave Technologies Incorporated$180
- Takeda Pharmaceuticals U.S.A., Inc.$21
- Biodelivery Sciences International, Inc.$13
Across 5 payments — averaging $11,280 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GRT US Holding, Inc.$56K
What the payments were for
- Speaking & faculty fees$3,24069%
- Travel & lodging$1,16825%
- Food & beverage$3157%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 6 | $4,508 |
| Stimwave Technologies Incorporated | 1 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
How this compares
$4,723 in reported general payments places this provider in the 50th percentile of 278 interventional pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 384 | $96,546 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,792 | $74,638 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,096 | $71,913 |
| Morphine Sulfate ErMorphine Sulfate | 1,713 | $36,536 |
| Tizanidine Hcl | 1,313 | $23,184 |
| Fentanyl | 217 | $15,537 |
| Morphine Sulfate | 920 | $15,431 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $13,377 |
| Oxycodone Hcl | 490 | $10,113 |
| Xtampza ErOxycodone Myristate | 14 | $7,955 |
| Pregabalin | 89 | $7,898 |
| Buprenorphine Hcl | 36 | $4,841 |
| Methadone Hcl | 267 | $4,341 |
| Tramadol Hcl | 349 | $4,225 |
| OxycontinOxycodone Hcl | 12 | $3,653 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Brooksville
- Louis RasoJupiter$1.3M
- Ajay AntonyGainesville$1.1M
- Michael EspositoVero Beach$777K
- Nomen AzeemRiverview$650K
- Stanley GolovacMerritt Island$367K
- Sunil PanchalLutz$363K
- Robert BallPort Charlotte$246K
- Justin MannJacksonville$243K
- Giuseppe PaeseBoca Raton$180K
- Miguel de la GarzaNew Port Richey$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.